GHRH analogue is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-06-14. Numbers and descriptions here follow the published literature rather than marketing material.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
== Proposed benefits == AI agents have been proposed as a means of increasing personal and economic productivity, fostering greater innovation, and liberating users from monotonous tasks. However, Parmy Olson's Bloomberg opinion piece argued that agents are best suited for narrow, repetitive tasks with low risk. Conversely, researchers suggest that agents could be applied to web accessibility for people with disabilities, and researchers at Hugging Face propose that agents could be used for coordinating resources such as during disaster response. The R&D Advisory Team of the BBC views AI agents as being most useful when their assigned goal is uncertain. Erik Brynjolfsson suggests that AI agents are more valuable in enhancing, rather than replacing, humans.
The Jardin des Plantes is the home of the main galleries of the MNHN, and a division of the museum, which was born there. The garden was founded by Louis XIII 1635 as the Royal Garden of medicinal plants, under the direction of the royal physician. In the early 18th century, the chateau of the gardens was enlarged to house the collections of the royal pharmacist. In 1729, this collection was broadened into the Cabinet of Natural History, destined to receive the Royal collections dedicated to zoology and mineralogy. New plants and animal species were collected from around the world, examined, illustrated, classified, named and described in publications which were circulated across Europe and to America. An amphitheatre was constructed in the garden in 1787 to provide a venue for lectures and classes on the new discoveries. New greenhouses were built beginning in 1788, and the size of the gardens was doubled. The gardens served as the laboratory of scientists including Jean Baptiste Lamarck, author of the earliest theory of evolution, and were a base for major scientific expeditions by Nicolas Baudin, Alexander von Humboldt, Jules Dumont d'Urville and others throughout the 18th and 19th century. The gardens today include a large formal garden planted in geometric designs; and two enormous greenhouses, keeping tropical plants at a steady temperature of 22 degrees Celsius. The Alpine gardens present plants coming from Corsica, the Caucasus, North American and the Himalaya. The gardens of the School of Botany contain 3,800 species of plants, displayed by genre and family.
This is a list of standalone video games that have been ported from a modification of another video game, and/or that are entirely based on a modification of another video game. A game is considered standalone when it does not require the purchase or installation of any other game (including separate engine software such as the Source SDK) in order to run.
They can be synthesized/released and broken down again in specific reactions by enzymes or ion channels. Some (such as Ca2+) can be stored in special organelles and quickly released when needed. Their production/release and destruction can be localized, enabling the cell to limit space and time of signal activity.
Sources: en.wikipedia.org
=== Laboratory === Details of the first total synthesis of prodigiosin were published in 1962, confirming the chemical structure. As with the biosynthesis, the key intermediate was the A-B aldehyde shown in Figure 5. This aldehyde has subsequently been prepared by other methods and used to make prodigiosin and related natural products.
Theodor W. Adorno (; German: [ˈteːodoːɐ̯ aˈdɔʁno] ; born Theodor Ludwig Wiesengrund; 11 September 1903 – 6 August 1969) was a German philosopher, cultural, and music critic. He was a leading member of the Frankfurt School of critical theory, whose work has come to be associated with thinkers such as Ernst Bloch, Walter Benjamin, Max Horkheimer, Erich Fromm, and Herbert Marcuse, for whom the works of Sigmund Freud, Karl Marx, and G. W. F. Hegel were essential to a critique of modern society. As a critic of both fascism and what he called the culture industry, he authored numerous works—such as Dialectic of Enlightenment (1947), Minima Moralia (1951), and Negative Dialectics (1966)—that strongly influenced the European New Left. In an intellectual climate shaped by existentialism and logical positivism, Adorno developed a dialectical conception of history and philosophy that challenged the foundations of both, anticipating the divide that would later emerge between the analytic and continental traditions. As a classically trained musician, Adorno studied composition with Alban Berg of the Second Viennese School, influenced by his early admiration for the music of Arnold Schoenberg. Adorno's commitment to avant-garde music formed the backdrop of his subsequent writings and led to his collaboration with Thomas Mann on the latter's novel Doctor Faustus (1947), while the two men lived in California as exiles during the Second World War.
Glutathione disulfide (GSSG) is a disulfide derived from two glutathione molecules. In living cells, glutathione disulfide is reduced into two molecules of glutathione with reducing equivalents from the coenzyme NADPH. This reaction is catalyzed by the enzyme glutathione reductase. Antioxidant enzymes, such as glutathione peroxidases and peroxiredoxins, generate glutathione disulfide during the reduction of peroxides such as hydrogen peroxide (H2O2) and organic hydroperoxides (ROOH):
== Types == Hydroquinone is a commonly used agent in skin whiteners. The European Union banned it from cosmetics in 2000. It works by decreasing melanin production. Tretinoin, also known as all-trans retinoic acid, may be used to whiten specific areas. It may be used in combination with steroids and hydroquinone. Alpha hydroxy acid (AHA) is used as a skin bleacher. Its biochemical mechanism is unclear. Side effects may include sun sensitivity, skin redness, thickening, or itching. Low concentrations may be used in cosmetics. Kojic acid has been found to be an effective lightener in some studies and is also allowed to be used in cosmetics. Side effects include redness and eczema. Glutathione is the most common agent taken by mouth to whiten the skin. It can be used as a cream. It is an antioxidant normally made by the body. Whether or not it actually works is unclear as of 2019. Due to side effects that may result from intravenous use, the government of the Philippines recommends against such use. One 2017 review found tentative evidence of benefit of tranexamic acid in melasma. Another 2017 review found that evidence to support its use was insufficient. Azelaic acid may be a second-line option for melasma. Decapaptide-12 and related peptides which act as tyrosinase inhibitors have been used as skin-lightening agents. A number of types of laser treatments have been used in melasma with some evidence of benefit. Reoccurrence is common, and certain types of lasers can result in more pigmentation.
=== Aortic regurgitation === The prevalence of aortic regurgitation also increases with age. Moderate to severe disease has a prevalence of 13% in patients between the ages of 55 and 86. This valve disease is primarily caused by aortic root dilation, but infective endocarditis has been an increased risk factor. It has been found to be the cause of aortic regurgitation in up to 25% of surgical cases.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.